The inhibition of Th2 cytokines by dupilumab may activate Th/Tc1 cells and CD8+CD49a+ tissue-resident memory T cells in small vitiligo lesions, potentially leading to the expansion of NSV-affected skin patches. Here, CD8A is linked to vitiligo.